New Triple-Threat treatment trial for tough esophageal cancer
NCT ID NCT07481058
First seen Apr 10, 2026 · Last updated Apr 22, 2026 · Updated 2 times
Summary
This study is testing whether adding an experimental drug called KC1036 to standard immunotherapy and chemotherapy works better for people with advanced esophageal cancer that has returned or spread. It will involve 60 adults who haven't had prior treatment for their advanced disease. Researchers want to see if this three-drug combination helps shrink tumors and control the cancer longer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Hospital, Chinese Academy of Medical Sciences
RECRUITINGBeijing, 100021, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.